Literature DB >> 8302279

A recombinant phenobarbital-inducible rat liver UDP-glucuronosyltransferase (UDP-glucuronosyltransferase 2B1) stably expressed in V79 cells catalyzes the glucuronidation of morphine, phenols, and carboxylic acids.

M Pritchard1, S Fournel-Gigleux, G Siest, P Mackenzie, J Magdalou.   

Abstract

V79 (Chinese hamster lung fibroblast) cell lines expressing a functional recombinant phenobarbital-inducible rat liver UDP-glucuronosyltransferase (UGT), i.e., UGT2B1, were established. Western blot analysis of positive colonies, using anti-rat liver UGT antibodies, revealed the presence of an immunoreactive polypeptide of the expected molecular mass of 52 kDa. The substrate specificity of the recombinant enzyme toward > 100 compounds was determined. Phenolic and alcoholic substrates included 4-methylumbelliferone, 4-hydroxybiphenyl, chloramphenicol, and testosterone, but a range of carboxylic acids of both endogenous (medium-chain saturated fatty acids, long-chain polyunsaturated fatty acids, and bile acids) and exogenous (profen nonsteroidal anti-inflammatory drugs, fibrate hypolipidemic agents, and sodium valproate) origin were also accepted, indicating that the enzyme was capable of forming both ether- and ester-type glucuronides from various structurally unrelated compounds. Determination of apparent kinetic constants for the glucuronidation by UGT2B1 of selected aglycones revealed a high maximal velocity toward the 3-position of morphine (49.3 +/- 2.2 nmol/min/mg of protein), compared with other known substrates such as 4-methylumbelliferone (2.67 +/- 0.11 nmol/min/mg of protein) or clofibric acid (0.06 +/- 0.02 nmol/min/mg of protein). To gain a better insight into the mechanisms underlying the apparently wide substrate specificity of UGT2B1, series of structurally related compounds were tested as potential substrates. The rate of glucuronidation of unbranched saturated fatty acids and omega,omega,omega-triphenylalkanoic acids increased progressively with increasing alkyl chain length and then declined, with the best substrates in these two homologous series being decanoic acid and 4,4,4-triphenylbutanoic acid, respectively. Glucuronidation of para-substituted phenols always proceeded at a higher rate than that of the corresponding para-substituted benzoic acids. This could mean that the aglycon hydroxyl group was better positioned in the enzyme active site in the case of phenols. Alternatively, if the initial interaction with the enzyme required the aglycon to be in the protonated uncharged form, then the observation could be explained by the difference in ionization between phenols and benzoic acids at the incubation pH used. The introduction of a bulky alkyl group into the para-position led to increases of up to 300-fold in the rate of glucuronidation, probably as a result of the increased aglycon lipophilicity. Finally, the enzyme showed a degree of stereo- and regiospecificity, preferring (S)-ibuprofen to the R-enantiomer (Vmax/Km, 3.06 and 1.10 microliters/min/mg of protein, respectively) and glucuronidating lithocholic acid but not hyodeoxycholic acid, which differs by only a single hydroxyl group.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8302279

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  10 in total

1.  Dextromethorphan differentially affects opioid antinociception in rats.

Authors:  Shiou-Lan Chen; Eagle Yi-Kung Huang; Lok-Hi Chow; Pao-Luh Tao
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

2.  Xenobiotic Metabolism in Mice Lacking the UDP-Glucuronosyltransferase 2 Family.

Authors:  Matthew J Fay; My Trang Nguyen; John N Snouwaert; Rebecca Dye; Delores J Grant; Wanda M Bodnar; Beverly H Koller
Journal:  Drug Metab Dispos       Date:  2015-09-09       Impact factor: 3.922

3.  Alterations in hepatic mRNA expression of phase II enzymes and xenobiotic transporters after targeted disruption of hepatocyte nuclear factor 4 alpha.

Authors:  Hong Lu; Frank J Gonzalez; Curtis Klaassen
Journal:  Toxicol Sci       Date:  2010-10-08       Impact factor: 4.849

Review 4.  Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT).

Authors:  Kathleen M Knights; Andrew Rowland; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

5.  Novobiocin inhibits both UDP-glucuronosyltransferase and cytochrome P450-mediated enzyme activities in pig liver microsomes.

Authors:  D Villar; N Furusawa; M Monshouwer; A S Van Miert
Journal:  Vet Res Commun       Date:  1998-09       Impact factor: 2.459

6.  Inducibility of ethoxyresorufin deethylase and UDP-glucuronosyltransferase activities in two human hepatocarcinoma cell lines KYN-2 and Mz-Hep-1.

Authors:  A Abid; N Sabolovic; J Magdalou
Journal:  Cell Biol Toxicol       Date:  1996-04       Impact factor: 6.691

Review 7.  UDP-glucuronosyltransferase inhibitors.

Authors:  E Golovinsky; Z Naydenova; K Grancharov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Oct-Dec       Impact factor: 2.569

8.  Ketamine coadministration attenuates morphine tolerance and leads to increased brain concentrations of both drugs in the rat.

Authors:  T O Lilius; V Jokinen; M S Neuvonen; M Niemi; E A Kalso; P V Rauhala
Journal:  Br J Pharmacol       Date:  2015-06       Impact factor: 8.739

9.  Predicting plasma concentrations of bisphenol A in children younger than 2 years of age after typical feeding schedules, using a physiologically based toxicokinetic model.

Authors:  Andrea N Edginton; Len Ritter
Journal:  Environ Health Perspect       Date:  2008-11-14       Impact factor: 9.031

10.  Impact of fatty acids on human UDP-glucuronosyltransferase 1A1 activity and its expression in neonatal hyperbilirubinemia.

Authors:  Ayako Shibuya; Tomoo Itoh; Robert H Tukey; Ryoichi Fujiwara
Journal:  Sci Rep       Date:  2013-10-09       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.